RS63837B1 - Heterociklična jedinjenja za lečenje bolesti - Google Patents

Heterociklična jedinjenja za lečenje bolesti

Info

Publication number
RS63837B1
RS63837B1 RS20221070A RSP20221070A RS63837B1 RS 63837 B1 RS63837 B1 RS 63837B1 RS 20221070 A RS20221070 A RS 20221070A RS P20221070 A RSP20221070 A RS P20221070A RS 63837 B1 RS63837 B1 RS 63837B1
Authority
RS
Serbia
Prior art keywords
optionally substituted
compound
group
pharmaceutically acceptable
solvate
Prior art date
Application number
RS20221070A
Other languages
English (en)
Serbian (sr)
Inventor
Raju Mohan
John Nuss
Jason Harris
Original Assignee
Oppilan Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oppilan Pharma Ltd filed Critical Oppilan Pharma Ltd
Publication of RS63837B1 publication Critical patent/RS63837B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20221070A 2015-11-13 2016-11-11 Heterociklična jedinjenja za lečenje bolesti RS63837B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease
EP16865156.0A EP3373931B1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
RS63837B1 true RS63837B1 (sr) 2023-01-31

Family

ID=58696139

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20221070A RS63837B1 (sr) 2015-11-13 2016-11-11 Heterociklična jedinjenja za lečenje bolesti

Country Status (22)

Country Link
US (4) US10683291B2 (enExample)
EP (2) EP4163281A1 (enExample)
JP (3) JP6933384B2 (enExample)
KR (1) KR102720397B1 (enExample)
CN (2) CN108463222B (enExample)
AU (2) AU2016353348A1 (enExample)
BR (1) BR112018009745B1 (enExample)
CA (1) CA3005236C (enExample)
DK (1) DK3373931T3 (enExample)
ES (1) ES2932049T3 (enExample)
HR (1) HRP20221417T1 (enExample)
HU (1) HUE060594T2 (enExample)
IL (1) IL259297B2 (enExample)
LT (1) LT3373931T (enExample)
MX (1) MX382092B (enExample)
PL (1) PL3373931T3 (enExample)
PT (1) PT3373931T (enExample)
RS (1) RS63837B1 (enExample)
RU (1) RU2727194C2 (enExample)
SI (1) SI3373931T1 (enExample)
SM (1) SMT202300062T1 (enExample)
WO (1) WO2017083756A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4163281A1 (en) 2015-11-13 2023-04-12 Oppilan Pharma Ltd. Process for preparing heterocyclic compounds for the treatment of disease and intermediate compounds used therein
EP3625230A1 (en) * 2017-05-17 2020-03-25 Oppilan Pharma Ltd. Prodrugs for the treatment of disease
US20210163485A1 (en) * 2017-05-17 2021-06-03 Oppilan Pharma Ltd. Heterocyclic Compounds for the Treatment of Disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
JP2025524598A (ja) * 2022-07-06 2025-07-30 オピラン ファーマ リミテッド S1p受容体モジュレーターの結晶形態
CN120835886A (zh) * 2023-01-13 2025-10-24 奥比兰制药有限公司 S1p受体调节剂的制备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US20100249071A1 (en) 2009-03-30 2010-09-30 Exelixis, Inc. Modulators of S1P and Methods of Making And Using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
PH12012500938A1 (en) 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CN103124727B (zh) * 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
CN103998451A (zh) 2011-10-20 2014-08-20 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
EP3074377B1 (en) 2013-11-27 2018-10-17 Genentech, Inc. Substituted benzamides and methods of use thereof
EP4163281A1 (en) 2015-11-13 2023-04-12 Oppilan Pharma Ltd. Process for preparing heterocyclic compounds for the treatment of disease and intermediate compounds used therein

Also Published As

Publication number Publication date
CN114149424A (zh) 2022-03-08
JP6933384B2 (ja) 2021-09-08
US20220227767A1 (en) 2022-07-21
WO2017083756A1 (en) 2017-05-18
AU2021202945B2 (en) 2022-06-23
HUE060594T2 (hu) 2023-03-28
US20190241556A1 (en) 2019-08-08
KR20180095811A (ko) 2018-08-28
PL3373931T3 (pl) 2023-02-06
JP2023017862A (ja) 2023-02-07
BR112018009745A2 (pt) 2018-11-06
IL259297A (en) 2018-07-31
CA3005236C (en) 2024-02-20
BR112018009745B1 (pt) 2023-09-26
BR112018009745A8 (pt) 2019-02-26
SI3373931T1 (sl) 2023-02-28
LT3373931T (lt) 2023-03-10
DK3373931T3 (da) 2022-11-28
EP3373931B1 (en) 2022-09-28
ES2932049T3 (es) 2023-01-09
AU2016353348A1 (en) 2018-07-05
JP2021191753A (ja) 2021-12-16
HRP20221417T1 (hr) 2023-02-03
MX382092B (es) 2025-03-04
EP4163281A1 (en) 2023-04-12
EP3373931A4 (en) 2019-04-03
JP7445325B2 (ja) 2024-03-07
MX2018005987A (es) 2018-11-29
IL259297B (en) 2022-11-01
CA3005236A1 (en) 2017-05-18
US10683291B2 (en) 2020-06-16
EP3373931A1 (en) 2018-09-19
RU2018121416A3 (enExample) 2019-12-17
IL259297B2 (en) 2023-03-01
KR102720397B1 (ko) 2024-10-21
CN108463222A (zh) 2018-08-28
SMT202300062T1 (it) 2023-03-17
PT3373931T (pt) 2022-12-06
AU2021202945A1 (en) 2021-06-03
US20230339944A1 (en) 2023-10-26
JP7174963B2 (ja) 2022-11-18
CN114149424B (zh) 2025-05-13
CN108463222B (zh) 2021-10-22
RU2727194C2 (ru) 2020-07-21
RU2018121416A (ru) 2019-12-13
US20200325135A1 (en) 2020-10-15
JP2018535261A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
JP7174963B2 (ja) 疾患の処置のための複素環化合物
JP6522602B2 (ja) Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
US7122557B2 (en) Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
KR102336371B1 (ko) 테트라졸론-치환된 디히드로피리디논 mgat2 억제제
JP2023550543A (ja) 二環式化合物及び疾患の治療のためのその使用
EP3625230A1 (en) Prodrugs for the treatment of disease
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
WO2024077057A1 (en) Phenyl oxy amide kinase inhibitors
HK40070316A (en) Heterocyclic compounds for the treatment of disease
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease
HK1260375B (zh) 用於治疗疾病的杂环化合物
CN111094227A (zh) 丙烯酸类似物